Results 241 to 250 of about 34,307 (290)

Antiviral Inflammasomes and How to Find Them. [PDF]

Viruses
Wuerth JD, Schmidt FI.
europepmc   +1 more source

Membralin Assembles a MAN1B1-VCP Complex to Target Foreign Glycoproteins from the Endoplasmic Reticulum to Lysosomes for Degradation. [PDF]

Adv Sci (Weinh)
Zhang J, Lu X, Li S, Wang T, Ahmad I, Zheng YH.   +5 more
europepmc   +1 more source

Unveiling the Impact of Drug-Sensitive Mutations on HIV-1 Protease Dynamics: A Molecular Dynamics Simulation Study of the T12A, L63Q, and H69N Variants. [PDF]

Int J Mol Sci
Srihi H, Abid N, Fabeni L, Precone C, Déméné H, Chillemi G.   +5 more
europepmc   +1 more source

Development of HIV-1 Fusion Inhibitors Targeting gp41

Current Medicinal Chemistry, 2014
The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41.
Fangwei Shao
exaly   +6 more sources

Inhibition of HIV-1 by Fusion Inhibitors

Current Pharmaceutical Design, 2010
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion.
Dirk, Eggink, Ben, Berkhout, Rogier W, Sanders   +2 more
core   +4 more sources

Entry and fusion inhibitors of HIV

Expert Opinion on Therapeutic Patents, 2004
Considerable advances have been made towards finding compounds that are active as inhibitors of the entry and fusion of HIV. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors, in addition to fusion and attachment blockers.
S. Rusconi, E. Bulgheroni, P. Citterio
openaire   +2 more sources

Inhibiting HIV-1 Entry with Fusion Inhibitors

Current Medicinal Chemistry, 2003
In recent years, tremendous progress has been made in understanding the HIV-1 entry process in which the viral and cellular membranes are fused, resulting in the subsequent delivery of the viral genome into the host cell. The mechanistic insight gained from these studies has led to the formulation of exciting new approaches for therapeutic intervention.
C E, Baldwin, R W, Sanders, B, Berkhout
core   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Fusion/entry inhibitors as therapies for HIV

Expert Opinion on Emerging Drugs, 2001
A combination of three or more antiretroviral drugs, commonly termed 'highly active antiretroviral therapy' (HAART), has become the standard-of-care treatment for HIV-related disease in the developed world. Since its initiation in the mid 1990s, HAART has led to substantial reductions in both mortality and morbidity.
Mike Westby
exaly   +3 more sources

Inhibitors of HIV cellular fusion

Expert Opinion on Therapeutic Patents, 2000
HIV infection continues to be a major global health problem. Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance and adverse side effects following prolonged use. Thus, we are faced with the need to develop new antiviral strategies with more potent compounds
Jim A Turpin, O M Zack Howard
exaly   +2 more sources